These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1471076)

  • 21. DDAVP in uremia.
    Vicente V; Alberca I; Macias JF; Lopez Borrasca A
    Nephron; 1984; 36(2):145-6. PubMed ID: 6420716
    [No Abstract]   [Full Text] [Related]  

  • 22. Tissue plasminogen activator enhancing activity of vasopressin analogues in monkeys: structure-activity study.
    Vilhardt H; Barth T
    J Recept Res; 1993; 13(1-4):305-11. PubMed ID: 8450495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The initial release of t-PA induced by dDAVP is more important with low molecular weight heparin than with unfractionated heparin.
    Schved JF; Gris JC; Sarlat C
    Thromb Haemost; 1991 Jan; 65(1):109. PubMed ID: 1850874
    [No Abstract]   [Full Text] [Related]  

  • 24. Desmopressin stimulates the expression of P-selectin on human platelets in vitro.
    Wun T; Paglieroni TG; Lachant NA
    J Lab Clin Med; 1995 Oct; 126(4):401-9. PubMed ID: 7561450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity.
    Horstman LL; Valle-Riestra BJ; Jy W; Wang F; Mao W; Ahn YS
    Thromb Res; 1995 Jul; 79(2):163-74. PubMed ID: 7676403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced response of uraemic bleeding time to repeated doses of desmopressin.
    Canavese C; Salomone M; Pacitti A; Mangiarotti G; Calitri V
    Lancet; 1985 Apr; 1(8433):867-8. PubMed ID: 2858723
    [No Abstract]   [Full Text] [Related]  

  • 27. Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia.
    Rydzewski A; Rowiński M; Myśliwiec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):823-30. PubMed ID: 2436997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-Deamino-8-D-arginine vasopressin lowers protein C activity in uremics.
    Aunsholt NA; Schmidt EB; Stoffersen E
    Nephron; 1989; 53(1):6-8. PubMed ID: 2506477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
    Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products.
    D'Angelo A; Capitanio A; Smith JB; Valsecchi C; Mannucci PM
    Thromb Haemost; 1983 Feb; 49(1):64-5. PubMed ID: 6687766
    [No Abstract]   [Full Text] [Related]  

  • 32. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
    Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
    Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desmopressin and super platelets.
    Pecci A; Balduini CL
    Blood; 2014 Mar; 123(12):1779-80. PubMed ID: 24652962
    [No Abstract]   [Full Text] [Related]  

  • 34. On the slow in vitro inhibition of tissue plasminogen activator in plasma and platelet lysates.
    Felding P; Nilsson IM
    Thromb Haemost; 1989 Jun; 61(3):539. PubMed ID: 2508262
    [No Abstract]   [Full Text] [Related]  

  • 35. Normal response to DDAVP in patients with plathology of the hypothalamoneurohypophyseal axis.
    Vincente V; Corrales J; Miralles J; Alberca I
    Thromb Res; 1987 Mar; 45(5):695-7. PubMed ID: 3109066
    [No Abstract]   [Full Text] [Related]  

  • 36. The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator.
    Kaneko M; Mimuro J; Matsuda M; Sakata Y
    Biochem Biophys Res Commun; 1991 Aug; 178(3):1160-6. PubMed ID: 1908232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
    Juhl A
    Nephron; 1986; 43(4):305-6. PubMed ID: 3090461
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetyl salicylic acid intake in healthy volunteers.
    Lethagen S; Rugarn P
    Thromb Haemost; 1992 Jan; 67(1):185-6. PubMed ID: 1615477
    [No Abstract]   [Full Text] [Related]  

  • 39. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders.
    Kobrinsky NL; Israels ED; Gerrard JM; Cheang MS; Watson CM; Bishop AJ; Schroeder ML
    Lancet; 1984 May; 1(8387):1145-8. PubMed ID: 6144876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemostasis, platelet function and serotonin in acute and chronic renal failure.
    Malyszko J; Malyszko JS; Pawlak D; Pawlak K; Buczko W; Mysliwiec M
    Thromb Res; 1996 Sep; 83(5):351-61. PubMed ID: 8873344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.